Device-related clinical outcomes of the Photodynamic Bone Stabilization System in the treatment of pathologic humerus fractures: A Meta-Analysis of The Literature
Main Article Content
Abstract
Objectives: The humerus is one of the most common sites of metastatic disease to bone. Over the past decade, however, a novel, non-metallic Photodynamic Bone Stabilization System (PBSS) has become available, creating growing interest in the use of the system to treat pathologic fractures. We aimed to analyze device-related clinical outcomes extracted from a meta-analysis of the literature to determine appropriate use cases in the treatment of pathologic humerus lesions.
Methods: Using predetermined inclusion and exclusion criteria, Pubmed, Medline and Embase electronic databases were searched in January 2023 for relevant articles relating to IlluminOss implants for humerus pathologic fracture. Keywords used were “IlluminOss” OR “Photodynamic Bone Stabilization System” AND “Fracture”.
Results: 114 articles were identified and screened. A total of 67 humerus lesions stabilized with IlluminOss from 5 studies were included for review. 36 (54%) of these patients were female. There were 51 complete pathological fractures and 16 impending fractures. Sixteen of 67 (24%) patients had implant-related complications, including broken implants (13), traumatic periprosthetic fracture (1), proximal migration of implant (1), and intra-articular penetration by a supplemental screw (1). All complications occurred in the setting of complete pathological fractures (P value = 0.01). The distal humerus was the most common location (60%) for complications (P value = 0.02). Complications trended to occur more frequently in females (75%) and patients with renal cell carcinoma (33%), however, these factors were not statistically significant.
Conclusions: The IlluminOss implant has been successfully used to treat many pathological humerus fractures, however, the rate of implant-related complications was high in complete pathologic fractures located in the distal humerus. The most common mode of failure was broken implant. Orthopedic surgeons should consider complete pathologic fractures in the distal humerus as high risk for implant failure and may need to augment their stabilization or choose alternative means of treatment.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Zimel MN, Hwang S, Riedel ER, et al. Carbon fiber intramedullary nails reduce artifact in postoperative advanced imaging. Skeletal Radiol. 2015;44(9):1317-1325. doi:10.1007/s00256-015-2140-x
3. Zoccali C, Soriani A, Rossi B, et al. The Carbofix™ “Piccolo Proximal femur nail”: A new perspective for treating proximal femur lesion. A technique report. J Orthop. 2016;13(4):343-346. doi:10.1016/j.jor.2016.08.012
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev.2001;27(3):165-176. doi:10.1053/ctrv.2000.0210
5. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867. doi:10.1002/cncr.22918
6. Wedin R, Hansen BH, Laitinen M, et al. Complications and survival after surgical treatment of 214 metastatic lesions of the humerus. J Shoulder Elbow Surg. 2012;21(8):1049-1055. doi:10.1016/j.jse.2011.06.002
7. Weiss KR, Bhumbra R, Biau DJ, et al. Fixation of pathological humeral fractures by the cemented plate technique. J Bone Joint Surg Am. 2011;93(12):1093-1097. doi:10.2106/JBJS.J.01032
8. IlluminOss Medical. IlluminOss Medical granted FDA marketing clearance for the IlluminOss® bone stabilization system. GlobeNewswire News. Published January 9, 2018. Accessed March 15, 2024. http://www.globenewswire.com/news-release/2018/01/09/1286073/0/en/IlluminOss-Medical-Granted-FDA-Marketing-Clearance-for-the-IlluminOss-Bone-Stabilization-System.html
9. Vegt P, Muir JM, Block JE. Photodynamic bone stabilization system: A minimally invasive, percutaneous intramedullary polymeric osteosynthesis for simple and complex long bone fractures. Med Devices (Auckl). 2014;7:453-461. doi:10.2147/MDER.S67681
10. Hoellwarth JS, Weiss K, Goodman M, et al. Evaluating the reoperation rate and hardware durability of three stabilizing implants for 105 malignant pathologic humerus fractures. Injury. 2020;51(4):947-954. doi:10.1016/j.injury.2020.01.030
11. Albertini U, Conti A, Ratto N, et al. Electrochemotherapy and simultaneous photodynamic bone stabilization of upper limbs in metastatic renal cancer disease: Case report and literature review. Case Rep Med. 2020;2020:8408943. doi:10.1155/2020/8408943
12. Krumme J, MacConnell A, Wallace M, et al. Early experience in pathologic humerus fracture treated with the photodynamic bone stabilization system shows limitations related to patient selection. Orthopedics. 2021;44(3):154-159. doi:10.3928/01477447-20210427-03
13. Zoccali C, Attala D, Pugliese M, et al. The IlluminOss® photodynamic bone stabilization system for pathological osteolyses and fractures of the humerus: Indications, advantages, and limits in a series of 12 patients at 24 months of minimum follow-up. BMC Musculoskelet Disord. 2021;22(1):63. doi:10.1186/s12891-021-03957-1
14. Perisano C, Greco T, Fulchignoni C, et al. The IlluminOss® system: A solution in elderly patients with upper limbs bone metastases. Eur Rev Med Pharmacol Sci. 2022;26(1 Suppl):119-126. doi:10.26355/eurrev_202201_27517
15. Gausepohl T, Pennig D, Heck S, et al. Effective management of bone fractures with the Illuminoss photodynamic bone stabilization system: Initial clinical experience from the European Union registry. Orthop Rev (Pavia). 2017;9(1):6988. doi:10.4081/or.2017.6988